SNP Array vs Multiplex Amplicon Panel for Large-Cohort Genotyping: Which Fits Your Project?

Figure 1. Fixed genome-wide marker coverage and flexible targeted sequencing answer different large-cohort genotyping questions.

A SNP array usually fits projects that need a standardized, fixed set of many markers across every sample. A multiplex amplicon panel usually fits projects that need tens to hundreds of known variants, flexible target selection, or sequence-level observations within short predefined regions. Neither technology is universally better. The useful choice follows from the marker objective, sample count, expected reuse, available DNA, and the analyses that must be supported.

For example, an approximately 85K human array may be appropriate for genome-wide common-variant profiling and GWAS-oriented cohorts. An amplicon panel may be a better match for 80–500 known SNPs across 2,000 samples, a parentage panel, a stock-assignment assay, or repeated genotyping of candidate loci. If the project must discover variants outside predefined amplicons, targeted capture or broader sequencing should enter the comparison.

TL;DR

1. Choose an array when the project needs a stable genome-wide backbone and standardized calls across a large cohort.
2. Choose a multiplex amplicon panel when the markers are already known and target flexibility matters more than genome-wide coverage.
3. Arrays generally do not reveal sequence variation between their predefined probes; amplicon sequencing can observe variants inside the amplified intervals.
4. Panel development and multiplex balance are part of an amplicon project, while manifest fit and ancestry coverage are central to an array project.
5. Compare total project cost and repeat-use value, not only per-sample laboratory price.

The Direct Comparison

The table below separates platform characteristics from project consequences. Exact capacity and input requirements depend on the selected assay and validated workflow, so final specifications should be confirmed for the actual cohort.

For projects that need help beyond these two choices, the existing SNP arrays versus low-pass and deep WGS guide adds sequencing breadth to the decision. The Hybrid Capture versus Amplicon Sequencing guide addresses a different comparison within targeted resequencing.

Choose Arrays for a Backbone

Arrays are attractive when every sample should be measured against the same broad marker manifest. Standardized content simplifies cohort merging, population-structure QC, relatedness checks, and association workflows. In human research, array genotypes can also provide the observed scaffold for phasing and imputation when the markers and reference panel are compatible.

An array is usually the stronger candidate when:

1. The study objective is genome-wide common-variant association or cohort characterization.
2. Thousands of samples must be compared at the same predefined loci.
3. The team needs a stable, versioned manifest rather than frequent marker changes.
4. Established genotype-calling and downstream formats fit the analysis environment.
5. A suitable reference panel and imputation plan can extend common-variant coverage.

The Human 85K SNP Genotyping Array Service is one example of a fixed human genome-wide configuration. Suitability still depends on ancestry, LD coverage, cohort size, and the final endpoint. For other organisms or marker densities, the broader SNP Genotyping Service is the better starting point.

Arrays become less attractive when the project needs only a small set of known variants, must change targets between versions, or requires sequence information within each region. A very large manifest can also generate data irrelevant to a narrow validation question. Paying for breadth is useful only when the analysis uses it.

Choose Amplicons for Known Targets

Multiplex amplicon sequencing concentrates reads on regions defined by primer pairs. It is well suited to repeated genotyping of known SNPs, short haplotypes, and marker sets developed from prior WGS, RAD-seq, GBS, or association studies. GT-seq demonstrated the core model: many samples, a compact SNP panel, dual indexing, pooled sequencing, and genotype calls derived from allele-specific read counts.

The main advantage is target control. Researchers can prioritize variants by rsID or coordinate, add short flanking sequence, and sometimes observe nearby variation within the same amplicon. The main cost is assay development. Primers interact in a multiplex, loci amplify at different efficiencies, and polymorphisms under primer sites can create allele dropout. A successful design therefore includes in-silico review, staged multiplex testing, and a representative pilot.

Amplicon panels are usually favored when:

1. The marker set is already known and compact.
2. The same targets will be genotyped repeatedly in large cohorts.
3. The project needs sequence-level confirmation within short regions.
4. Customization and panel revision are more important than a universal backbone.
5. The biological question involves parentage, assignment, monitoring, replication, or targeted follow-up.

The Targeted Resequencing Service supports projects that need sequence data from defined regions. If the objective is simple genotyping rather than regional sequencing, the final design may use a more focused workflow.

Figure 2. Sample number and marker number interact: a compact fixed marker set across thousands of samples points toward multiplex amplicon sequencing, while a broad genome-wide backbone points toward an array.

Marker Number Changes the Economics

"Large cohort" describes the number of samples, not the number of markers. Technology selection should place both dimensions on the same grid. An 85K-by-5,000 project and a 150-by-5,000 project have similar sample logistics but very different assay objectives and data volumes.

Do not infer price from the table. Total cost includes assay setup, failed markers, sample normalization, library preparation, sequencing, reruns, bioinformatics, data storage, and future reuse. An existing array may have little development overhead, while a custom amplicon panel invests more effort before production. Once validated, however, the targeted panel can become efficient for repeated cohorts.

Flexibility Has a Validation Cost

Custom target selection is valuable only when the selected loci can be amplified and interpreted reproducibly. Multiplex PCR can produce primer dimers, off-target products, uneven varying amplicon depth, and locus dropout. LaVerriere and colleagues emphasize design and implementation as connected activities, and recent studies continue to evaluate multiplex balance and sample-dependent performance.

A panel-development pilot should examine:

1. On-target read fraction and depth distribution across amplicons
2. Proportion of samples and loci meeting prespecified completeness rules
3. Allele balance at heterozygous sites
4. Concordance with orthogonal genotypes or known controls
5. Evidence of allele dropout, especially near primer-binding polymorphisms
6. Index balance, contamination controls, and repeatability across plates
7. Performance across the expected DNA quantity and quality range

An array pilot asks different questions: genotype-cluster separation, call completeness, sample identity, plate effects, and whether the manifest covers informative variation in the target population. The QC metrics at cohort scale resource provides a shared framework for documenting these evidence streams without pretending that the same metric applies to both technologies.

Discovery Scope Is Different

An array reports genotypes at predefined probes. An amplicon panel sequences defined intervals, which may reveal additional variation inside those intervals if coverage and analysis support it. That difference is useful but should not be overstated. An amplicon panel does not discover variants outside its targets, and primer failure can make a targeted interval effectively invisible.

For studies starting from discovery data, separate the phases:

1. Use WGS, RAD-seq, GBS, or another discovery strategy to identify candidate variants.
2. Filter markers for informativeness, LD, genome distribution, technical feasibility, and the downstream endpoint.
3. Select the production technology based on the final marker set and cohort scale.
4. Validate the locked panel in samples that represent the intended populations.

The GBS Service can support discovery-oriented reduced-representation projects, while the RAD-seq parentage resource explains how discovery data can feed parentage and assignment questions. Production genotyping should begin only after the marker set has passed biological and technical review.

Repeat Use Favors Stability

Recurring projects benefit from a versioned assay. Arrays provide an existing manifest, but a platform revision can change marker content. Amplicon panels are highly controllable after they are locked, yet adding or replacing primers can alter multiplex balance. Treat every material version change as a comparability event.

Maintain a release record with the marker list, coordinates, reference build, primer or probe identifiers, allele definitions, software versions, QC thresholds, and validation results. Use bridge samples across versions and plates. Technical replicates are particularly informative during development, after major panel changes, and when a new sample matrix is introduced.

Figure 3. Repeatable large-cohort genotyping depends on version control and bridge samples regardless of platform.

A Practical Selection Checklist

Before requesting a quote, provide enough detail for both options to be evaluated on the same basis:

1. Species, reference genome, and coordinate build
2. Sample number now and expected future sample number
3. Sample types, extraction methods, DNA quantity, and quality range
4. Marker count, rsIDs or coordinates, alleles, and flanking sequence
5. Whether the markers are fixed, likely to change, or still being discovered
6. Population composition and expected allele frequencies
7. Required outputs, including genotype tables, VCF, read data, or imputation-ready files
8. Need for novel variation inside or outside the selected targets
9. Planned downstream analyses and acceptance criteria
10. Frequency of repeat cohorts and need for cross-run comparability

If the central need is a fixed human genome-wide backbone, start with an array feasibility review. If the need is a custom set of known loci, request an amplicon feasibility review that includes primer design and pilot expectations. CD Genomics supports project-specific feasibility review for both routes.

Test the Decision with a Realistic Scenario

Imagine a program that expects several thousand research samples over multiple years and initially requests 300 known SNPs. An amplicon panel may fit the current marker list, but that answer changes if investigators expect frequent marker substitutions, need uniform genome-wide ancestry information, or must merge results with a legacy array cohort. Conversely, an array may produce much more data than the scientific question requires if only a stable shortlist will be used. Compare the full lifecycle: design and pilot effort, per-batch controls, failed-sample recovery, data storage, cross-version bridging, and downstream analysis—not only the quoted production price.

Before choosing, run a small representative pilot on both the easiest and most difficult sample classes. For an amplicon workflow, inspect locus dropout, read balance, off-target products, contamination controls, genotype concordance, and whether poor loci fail in specific populations because a primer-binding variant is present. For an array, inspect sample and marker call metrics, intensity or cluster behavior where available, replicate concordance, plate effects, and performance of priority loci. A threshold reported in another project is a starting point, not a universal acceptance rule; lock criteria before reviewing the pilot and relate each criterion to the intended analysis.

Troubleshooting should follow the failure pattern. Sample-wide failure suggests input quantity, integrity, inhibitors, identity, or processing problems. Locus-wide amplicon failure suggests primer design, multiplex competition, nearby variation, or mapping ambiguity. Plate-specific array failure suggests handling or batch effects. Population-specific failure on either platform can indicate ascertainment, probe or primer mismatch, or inappropriate marker selection. Redesign only after separating these patterns, and retain failed as well as successful observations in the review package.

Neither method establishes that an associated marker is causal. Arrays are useful for standardized genome-wide scaffolds and amplicon panels for focused repeated genotyping, but neither adds much when the marker set is still unstable and discovery remains the main objective. In that situation, sequence-based discovery followed by an independently validated production panel may be more defensible. Evidence from a different species, tissue source, or DNA-quality context should be treated as feasibility evidence, not a performance promise for the new cohort.

Frequently Asked Questions

This article and the services it describes are for research use only and are not intended for clinical diagnosis, treatment selection, or individual health assessment.

  Related Services

DNA Methylation Microarray for population genetics

SNP Genotyping Service

Human 85K SNP Genotyping Array Service

Sequencing

Whole Exome Sequencing for Population Genetics

Bioinformatics

Genetic Diversity Analysis

Genome-wide Association Analysis Service

  Download

Power Your Regulatory Discoveries with DAP-seq: A MYB-GLK Case Study

Off-Target Validation Available Now: Maximize Your CRISPR Success

Choose the DNA Methylation Microarray Service that Fits Your Needs- 270K or 935K?

2b-RAD Sequencing: Your Gateway to High-Density SNP Genotyping